The Rabbit Polyclonal anti-Ubiquilin 2 antibody has been validated for WB, ELISA, IHC and IF. It is suitable to detect Ubiquilin 2 in samples from Human and Rat.
Catalog No. ABIN7120457
Quick Overview for Ubiquilin 2 antibody (ABIN7120457)
UBQLN2
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
WB: 1:200-1:2000, IHC: 1:20-1:200,IF:1:20-1:200
Restrictions
For Research Use only
Format
Liquid
Buffer
PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C
Storage Comment
-20°C for 12 months (Avoid repeated freeze / thaw cycles.)
Expiry Date
12 months
Target
Ubiquilin 2 (UBQLN2)
Alternative Name
UBQLN2
Background
Synonyms:CHAP1, CHAP1/DSK2, Dsk2, DSK2 homolog, hPLIC 2, HRIHFB2157, LIC 2, N4BP4, PLIC 2, PLIC2, RIHFB2157, ubiquilin 2, Ubiquilin-2, UBQLN2 Background:Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system(UPS), autophagy and the endoplasmic reticulum-associated protein degradation(ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding(via UBA domain) to their polyubiquitin chains and by interacting(via ubiquitin-like domain) with the subunits of the proteasome(PubMed:10983987). Plays a role in the ERAD pathway via its interaction with ER-localized proteins FAF2/UBXD8 and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome(PubMed:24215460, PubMed:18307982). Involved in the regulation of macroautophagy and autophagosome formation, required for maturation of autophagy-related protein LC3 from the cytosolic form LC3-I to the membrane-bound form LC3-II and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion(PubMed:19148225, PubMed:20529957). Negatively regulates the endocytosis of GPCR receptors: AVPR2 and ADRB2, by specifically reducing the rate at which receptor-arrestin complexes concentrate in clathrin-coated pits(CCPs)(PubMed:18199683).